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A B S T R A C T
CRISPR/Cas9 (clustered regularly interspaced short palindromic repeat/clustered regularly interspaced short
palindromic repeat associated proteins 9) gene editing platform is a promising therapeutic tool for genetic
disorders, due to its ability to manipulate the pathogenic gene in genomic level and to easily target specific gene
by manipulating single-guide RNA. However, its successful delivery remains a challenge. Up to now, great efforts
have been made to explore an effective strategy for CRISPR/Cas9 delivery. But among those delivery methods,
physical methods are mainly operated on cultured cells thus limited to laboratorial use; viral vectors are hin-
dered by fetal immunogenic and carcinogenic effects thus dubious in clinical application. Therefore, cationic
polymeric vectors, with the ability to interact with CRISPR/Cas9 system to form a nanoformulation as a non-
viral approach, are attracting increasing attentions, due to advantages such as well protection of cargos, less
limitation in payload size, low immunogenicity or carcinogenicity, potential modifications for further functions,
and ease in mass production. In this review, the recent discoveries on polymeric vectors utilized in delivery of
CRISPR/Cas9 system will be summarized. With emphasis on advanced features of those polymeric vectors or
their nanoformulations to meet the demands of different CRISPR/Cas9 delivery forms (plasmid, mRNA or
protein), the detailed illustrations on their disease treatment applications, such as cancer, diabetes or antibiotic-
resistant infections, will also be reviewed.
1. Introduction
Gene therapy could manipulate DNA or RNA to treat and prevent
human diseases [1]. In the past years, researchers mainly focused on
restoring the function of missing gene by exogenous transgene expres-
sion or downregulation of pathogenic gene by RNAi molecules. How-
ever, the temporary effect of transgene or RNAi hinders its application
while the retention of disease-causing gene leads to a prominent ne-
gative effect to treatment. Recent developments of a novel gene editing
platform-CRISPR/Cas9 technology provide approaches to correct genic
disorders in genome level [2]. The system is composed of a nuclease
Cas9 and a single guide RNA (sgRNA). Guided by sgRNA, Cas9 can
target to a specific site of genome and cause double-strand breaks,
which will result in gene replacement or insert/delete mutations re-
spectively [3]. A number of reports have shown its application in gene
therapy to correct or disrupt the disease-causing genes and this
technology shows great potential in reforming therapy of numerous
human diseases including cancer, cardiovascular diseases, virus infec-
tion, antibiotic-resistant bacteria infection etc [4–6]. (see Table 1)
However, despite the merits of CRISPR/Cas9 system in gene
therapy, the success of its function relies on an effective intracellular co-
delivery of its two components: Cas9 nuclease and sgRNA. Cas9 can be
delivered in three forms: plasmid, mRNA or protein [7]. Cas9 plasmid
system is an appealing delivery strategy attributing to its low-cost
manipulation, simplicity and stability. Cas9 together with sgRNA, and
even HDR templates are able to be conveniently packed in the same
plasmid. However, its application is also hindered by several drawbacks
such as the long lag time for nuclear entry or expression as well as high
off-target effects on account of persistance expression of plasmid. The
delivery of Cas9 mRNA is an alternative option. It leads to quicker gene
editing efficiency and lower risk of off-target effect. However, the poor
stability of mRNA shadows its application and the short duration time
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may limit its gene editing efficiency. The delivery of Cas9 protein to-
gether with sgRNA is the most straightforward way to induce CRISPR/
Cas9 gene editing. This approach leads to the fastest genome editing as
well as the most transient functionality with minimal off-target effects
and toxicity. However, the large size of Cas9 protein brings incon-
venience to its delivery, as many delivery carriers such as viral vectors
are size limited.
In form of plasmid, Cas9 and sgRNA can be encoded in the same
plasmid to achieve co-delivery; in form of protein, the positive charged
Cas9 can interact with sgRNA and form ribonucleoprotein; while in
form of mRNA, the co-delivery should be achieved by vectors. It is
worth mentioned that Cas9 exhibits large molecular size in all forms,
while the effective condensation or package of Cas9 remains a chal-
lenge for vectors. Furthermore, as the function of CRISPR/Cas9 takes
place in nucleus, the nuclear transport is necessary for its delivery.
Hence, the vectors also have to show protection of the components,
especially for sensitive sgRNA. Fortunately, in recent years, a number of
delivery strategies were reported, varying from physical to chemical or
from viral to non-viral [8–17]. Among those strategies, physical
methods depend on naked cargos without any vectors’ protection.
When administered directly in vivo, the naked cargos are vulnerable to
enzymatic degradation and rapid clearance, which are limited to la-
boratorial use. For viral vectors, though those adeno-associated virus
and lentivirus exhibit excellent gene transfection efficiency, their ap-
plications are hindered by their limited packaging size, potential but
fetal immunogenic as well as carcinogenic effects [18–20].
Therefore cationic polymeric vectors, that exhibit low im-
munogenicity or carcinogenicity, protection of cargos, less limitation in
payload size, ease of production in large-scale, and ability to form na-
noformulation with CRISPR/Cas9 system, are excellent alternatives
[21]. In addition, polymers can achieve enhanced circulation time, cell
or tissue specific delivery and controlled release through further mod-
ification [22–32]. The above properties make polymeric vectors a
promising option for delivery of CRISPR/Cas9 platform in gene therapy.
In this review, we intend to summarize the current polymeric vectors
that are applied in CRISPR/Cas9 delivery and their applications in
treatment for human diseases as shown in Fig. 1, which are important
but not fully summarized yet.
2. Cationic polymers applied in CRISPR/Cas9 delivery
2.1. Cationic polymers applied in Cas9 plasmid delivery
Cas9 plasmid system is an appealing delivery strategy attributing to
its low-cost manipulation and simplicity. Cas9 together with sgRNA,
and even HDR templates are able to be conveniently packed in the same
plasmid. Moreover, plasmids exhibit higher stability compared with
proteins or mRNAs. However, plasmid system also suffers from several
drawbacks. Firstly, the nuclear entry and expression of plasmids require
for a long lag time before the therapeutic efficacy. Secondly, a long
persistence of the plasmids leads to the persistence of Cas9, which leads
to higher off-target effects. Thirdly, the requirement of nuclear entry of
Abbreviations
CRISPR Clustered regularly interspaced short palindromic repeat
Cas9 clustered regularly interspaced short palindromic repeat
associated proteins 9
sgRNA single guide ribonucleic acid
DNA deoxyribonucleic acid
DSBs double-strand breaks
HDR homologous directed repair
NHEJ non-homologous end-joining
PEI poly(ethylene imine)
PAMAM poly(amido amine)
LMWPEI low molecular weight PEI
HMWPEI high molecular weight PEI
PLGA poly(lactic-co-glycolic acid)
GO graphene oxide
CLAN cationic lipid assisted nanoparticle
PEG poly(ethylene glycol)
HPV human papillomavirus
Rb retinoblastoma protein
RNAi RNA interference
CML chronic myeloid leukemia
VEGFA vascular endothelial growth factor A
MTH1 mutT homolog1
BAFFR B-cell activating factor receptor
MRSA methicillin-resistant Staphylococcus Aureus
Table 1
A summary of current researches on polymeric nanoformulations for delivery of CRISPR/Cas9 system in gene therapy.
Formulation Delivery vector Targeting gene Cell type Application Ref
Plasmid Branched PEI 25 kDa Slc26a4 locus Neuro2a cells [33]
JetPEI polymer-based DNA transfection reagent E7 oncogene HPV16 positive cervical cancer cells (ect.
SiHa, Cask)
Cervical cancer [34]
PEI-β-CD EGFP gene HeLa-EGFP cells [35]
PEG-PEI-Cholesterol lipopolymer VEGFA gene OS cell (ect.K7M2) Osteosarcoma [36]
“core-shell” artificial virus MTH1 gene SKOV3 cells Ovarian cancer [37]
PPO-NMe3 and Pluronic F127 E7 oncogene HeLa cells Cervical cancer [38]
Polymeric and hybrid SiO2-coated capsules dTomato gene HEK293T-dTomato cells [39]
PEGylated nanoparticles based on the cationic α-helical
polypeptide
Plk1 gene HeLa and K562 cells Cancer [40]
Cationic lipid-assisted nanoparticle BCR-ABL fusion
gene
CML cell line K562 Chronic myeloid leukemia [41]
B220, BAFFR gene B cells rheumatoid arthritis [42]
Ntn1 gene macrophages T2D [43]
PEGylated chitosan copolymers HEK293 cells [44]
mRNA Cationic lipid-assisted nanoparticle NLRP3 gene macrophages Inflammatory diseases [45]
Protein Cr-Nanocomplex mecA gene MRSA Antimicrobial [46]
GO-PEG-PEI EGFP gene AGS-EGFP cell [47]
P(Asp-AED-ICA)−PEG HEK 293 cells MZ-CRC-1 cells RAW
264.7 cells U87-MG cells
[48]
[p(BAC-TET)]-based polymers HEK 293 cells HCT 116 cells RAW 264.7 cells [49]
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plasmids may lead to decreased genome editing efficiency.
Numerous cationic polymers were studied to delivery gene in the
past decade, among which some pioneers have been acknowledged as
classical transfection agents and widely used in the world, such as poly
(ethylene imine) (PEI). Those polymers possess high positive charge to
condense DNA and protect DNA from DNase and other physical and
chemical factors. The positive charge also endows the polymers with
high endosome escape to release the plasmid. Up to now, several
polymers have been tested to delivery CRISPR/Cas9 plasmid such as
poly(ethylenimine) (PEI), poly(amido amine) (PAMAM), polypeptide,
chitosan et al. and they exhibit good genome editing potential.
2.1.1. PEI based polymers in CRIEPR/Cas9 plasmid delivery
PEI, considered as a leading material for polymeric gene delivery
since the first successful application by Boussif et al. in 1995 [50], is
widely used as an effective transfection reagent and commercially
available at present, such as branched PEI and linear PEI, as shown in
Fig. 2A. In addition, many PEI based polymeric vectors have been ap-
plied in gene therapy clinical trials so far for their high transfection
efficiency and potential for further modification like BC819/PEI [51],
phIL-12/polyethyleneglycol–polyethyleneimine–cholesterol (PPC) [52]
and so on. The high concentration of amino groups endows PEI with a
high positive charge to strongly interact with plasmid and a strong
proton sponge effect to effectively escape from endosomes, thus it
possesses high gene transfection efficiency. It has been demonstrated
that simple 25-kDa branched PEI and commercial jet-PEI polymer-
based DNA transfection reagent could achieve delivery of Cas9/sgRNA
encoded plasmid successfully, according to studies respectively carried
out by Kim et al. [33] and Wang et al. [34]. However, its application is
shadowed by its high cytotoxicity as the research showed the decreased
cell viability down to 67.57%, at optimal N/P (nitrogen in polymer to
phosphor in plasmid) ratios of branched PEI, which called for further
improvement of the cationic polymeric structure [33].
It was reported that both the toxicity and transfection efficiency of
PEI were positively relative to the molecular weight. Lower transfection
efficiency is tolerable considering that a high level expression of Cas9
leads to high level off-target effect, so low molecular weight PEI
(LMWPEI) is worth trying in CRISPR/Cas9 plasmid delivery. In a re-
search carried out by Ping et al., LMWPEI was assembled with β-cy-
clodextrin through host–guest interaction. The complex showed similar
structure to high molecular weight PEI (HMWPEI), thereby exhibiting
effective transfection efficiency. More importantly, as compared with
HMWPEI, the much lower cytotoxicity nature allowed for high-dose-
level, repeated transfection. The β-cyclodextrin also enabled the
polymer for further modification to endow functions such as blood
stability and targeting capability to improve its delivery efficiency, as
showed in Fig. 2B [35].
Furthermore, further modifications on PEI can endow the polymers
with different functions such as biocompatibility, targeting ability for
superior gene delivery. A group of researchers functionalized LMWPEI
with polyethyleneglycol (PEG) and cholesterol (CHOL), obtaining a
kind of lipopolymer [36]. CHOL served as a biocompatible hydrophobic
lipid anchor to enhance the permeability through membrance [53] and
PEG served as a biocompatible hydrophilic segment to enhance the
stability and hemocompatibility of the lipopolymer. In addition, re-
searchers also modified the lipopolymer with cell-specific aptamers to
achieve target delivery of CRISPR/Cas9 system. Fluorination was also
an alternative way to modify LMEPEI [54]. The polymer became both
hydrophilic and hydrophobic after fluorinated, endowing it with high
phase-separation ability in both polar and nonpolar situation. So the
polymer had high affinity to lipid bilayer and could be easily taken up
by cells as well as escaped form endosomes. Li et al. coated fluorinated
LMWPEI with multifunctional RGD-R8-PEG-HA copolymer and formed
a polymeric “core-shell” complex for CRISPR/Cas9 target delivery [37].
The peptide RGD-R8 had high affinity to a kind of integrin receptor
overexpressed in tumor and tumor vessel, endowing the polymer with
tumor targeting ability. The PEG segment could make the complex
more stable and the anionic HA segment could reverse the cationic
charge of fluorinated LMWPEI to reduce nonspecific interaction with
compounds in human body. Furthermore, after HA degradation by
abundant hyaluronidase in cancer tissue, the cationic components in-
side would expose, leading to enhanced cellular uptake and endosome
Fig. 1. Schematic diagram of structure of cationic polymeric nanoformulation and their application in CRISPR/Cas9 system delivery for gene therapy and disease
treatments.
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Fig. 2. (A) The chemical structure of linear PEI and branched PEI. (Copyright 2015, Mary Ann Liebert, Inc) [55] (B) The schematic diagram of PEI-β-CD induced
CRISPR/Cas9 delivery. The polymer condenses plasmid through electrostatic interaction, forming polymer/plasmid complex. The complex could be taken up through
endocytosis and escape from endosome by proton sponge effect [35]. (Copyright 2018, WILEY‐VCH) (C) The synthesis process of fluorinated LMWPEI and RGD-R8-
PEG-HA copolymer. (Copyright 2016, American Chemical Society) [37] (D) The schematic diagram of the core-shell polymer complex induced CRISPR/Cas9
delivery. Fluorinated LMWPEI condensed plasmid to form the positive charged core and it was coated with multifunctional copolymer shell. The complex target to
tumor cells and the core could be exposed in tumor tissue to enhance cellular uptake and endosome escape (Copyright 2017, Ivyspring International Publisher). [56].
Fig. 3. (A) Illustration of polypeptide/dextran capsule induced CRISPER/Cas9 intracellular delivery and genome editing. The system caused DSBs which were further
repaired by NHEJ in dTomato gene, and often resulted in gene silencing. Left bottom: The TEM images of SiO2 coated and uncoated capsules showed that the
inorganic shell strongly enhanced the mechanical strength of the capsules. Right bottom: The CLSM images of gene editing efficiency in HEK293T-dTomato reporter
cells. The dTomato protein showed red signal, eGFP plasmid loaded in the capsule with CRISPER/Cas9 plasmid showed the green signal, Cy-7 in the capsules showed
the violet signal [39]. (Copyright 2017, Elsevier Inc) (B) Schematic diagram of the formation of polypeptide based nanoparticles and intracellular delivery of Cas9
expression plasmid and sgRNA. The polypeptide condensed CRISPR/Cas9 plasmid and formed nanoformulation together with PEG. The vector could be taken up by
cells through endocytosis as well as pore formation, thus leading to effective gene editing. (Copyright 2018, PNAS) [40].
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escape, as showed in Fig. 2C–D.
Besides to LMWPEI, other low-charge-density polymers were also
reported. Recently, Lao et al. modified poly(propylene oxide) (PPO) for
CRISPR/Cas9 plasmid delivery [38]. The quaternary ammonium were
added to the terminal of PPO to endow it with DNA loading ability and
the polymer was mixed with an amphiphilic tri-block copolymer
Pluronic F127 to form self-assembled micelles. The system targeted E7
gene in human papillomavirus and showed efficient gene knockdown,
which represented a positive example of cationic polymeric vectors.
2.1.2. Polypeptide based polymers in CRISPR/Cas9 plasmid system delivery
Polypeptides, in which amino acids are linked through peptides
bonds, are protein -mimicking polymers that are biodegradable and
biocompatible. When composed of alkaline/acidic amino acids or
modified with charged groups, those polymers are able to condense
oppositely charged drugs and biomolecules, such as genes [57]. It has
already confirmed that polyarginine [58], polylysine and other poly-
cationic amino acids were qualified for gene delivery and recently they
were tested for CRISPR/Cas9 plasmid system. Timin et al. designed a
polymeric capsule consisting of polyarginine and dextran [39]. The
capsule was formed through layer-by-layer electrostatic self-assembly
and exhibit excellent stability, large loading ability and good bio-
compatibility compared with other vectors, as showed in Fig. 3A. Some
peptides with specific functions could be decorated for gene delivery,
remaining their bio-functions for enhanced delivery efficiency. Wang
et al. modified a kind of α-helical polypeptide which possessed helicity-
associated cell-penetrating ability with some cationic side-chain groups
for plasmid/sgRNA delivery [40]. The polypeptide could be taken up by
cells through endocytosis as well as pore formation, as showed in
Fig. 3B. The researchers demonstrated that the cell-penetrating ability
of this polypeptide could induce stronger cellular uptake.
2.1.3. Cationic lipid assisted PLGA nanoparticles in CRISPR/Cas9 plasmid
delivery
Poly(lactic-co-glycolic acid) (PLGA) is a kind of widely used bio-
degradable polymers as its hydrolysates are glycolic acid and lactic acid
that can be easily metabolized by human bodies, as showed in Fig. 4A
[59]. Few toxicity effects are found in the use of PLGA in human body,
so the application of PLGA as delivery systems and biomaterials has
been approved by the US FDA. What's more, the degradation time of
PLGA can be changed from days to years through tuning the relative
ratio of glycolic and lactic acid or the molecular weight of the copo-
lymer therefore achieving a sustained release of its contents [60–64].
Those above properties make PLGA an efficient sustained release
delivery system for drugs and genes. However, one main drawback of
PLGA is its negative charge that leads to poor cellular uptake as well as
endosome escape [65]. In order to enhance the permeability of PLGA
particles, positive charged agents are added into the system, such as
cationic lipids [66]. Lipids have been utilized as delivery systems in the
shape of liposomes for their easy preparation, high biocompatibility
and variable surface modification and it is reported that lipid can be
applied combined with polymers, resulting in lipopolyplexes and lipid-
polymer hybrid nanoparticles which show both advantages. Recently a
serious of researches were carried out by Wang et al. that applied a kind
of cationic cholesterol assisted PLGA nanoparticles (CLAN) as CRISPR/
Cas9 plasmid delivery systems, as showed in Fig. 4B [41–43]. Those
nanoparticles composited of a PEG modified PLGA/cationic cholesterol
were prepared and exhibited gene editing efficiency in macrophages,
CML cells and B cells.
2.1.4. Chitosan in CRISPR/Cas9 plasmid delivery
Chitosan is a kind of natural polysaccharide composited of repeating
units of glucosamine and N-acetyl-glucosamine. It is widely considered
as a nontoxic and biodegradable polymer with positive charge thus
suitable for gene delivery vectors [67]. In addition, chitosan is mu-
coadhesive. Mucus is a blend of molecules such as salts, lysozyme,
mucins and exhibits high viscoelastic properties and negative charge in
physiological condition, affecting drugs and particles permeability by
forming physical barrier as well as interacting electrostatically with
cationic polymers. With mucoadhesion, chitosan shows greater poten-
tial in mucosal delivery. So far it has been demonstrated by Zhang et al.
that PEGylated chitosan nanocomplexes loaded with Cas9 plasmids
exhibited high mucoadhension and remained most physicochemical
properties after nebulization, indicating the feasibility to deliver
CRISPR/Cas9 system by inhalation, as showed in Fig. 5 [44].
2.2. Cationic polymers applied in Cas9 mRNA delivery
The delivery of Cas9 mRNA is an alternative option. The use of
mCas9 leads to relatively quick gene editing efficiency as it avoids the
need for nuclear entry and DNA transcription. This strategy also de-
creases the risk of potential off-target effects because the quick clear-
ance of mRNA results in transient expression of Cas9. In addition, in
vitro transcription provides an easy way for manipulation of mRNA.
However, the poor stability of mRNA shadows its application and the
short duration time may limit its gene editing efficiency [68,69].
In this condition, the properties of polymers like high transfection
efficiency and protection form degradation make them suit the de-
mands for Cas9 mRNA delivery. Recently Wang et al. developed a kind
of cationic cholesterol assisted PLGA nanoparticles (CLAN) composed of
PEG-PLGA and BHEM-chol as CRISPR/Cas9 mRNA delivery systems, as
shown in Fig. 6 [45]. The cationic lipids were to neutralize the negative
charge of the polymer and the nanoparticles were covered with PEG for
prolonged circulation. To fabricate the suitable CLAN, they designed a
library of CLANs with different PEG densities and surface charges and
then tested the in vivo macrophage uptake to screen the optimized. The
results showed that the nanoparticle with the highest surface charge
and relatively lower PEG density exhibited the best macrophage uptake.
Fig. 4. (A) The metabolism pathway of PLGA. (Copyright 2012, Elsevier B.V.) [59] (B) The diagram of cationic-BHEM assisted PEG-PLGA nanoparticles. (Copyright
2018, American Chemical Society) [43].
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Fig. 5. (A) Synthesis of PEGylated Chitosan. (Copyright 2018, American Chemical Society) [44] (B) The properties of the PEGylated chitosan/plasmid nanocomplex.
The nanocomplex exhibits high loading capacity, protection of payloads from DNase I, mucus permeation and aerosolization ability and effective intracellular uptake.
(Copyright 2018, American Chemical Society) [44].
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It was reasonable because high positive charge led to strong interaction
with cyto-membrane. However, PEG density was not the lower the
better because the shield of positive charge decreased the interaction
with cell membrance and enhanced the stability and hemo-compat-
ibility as well.
2.3. Cationic polymers applied in Cas9 protein delivery
The most straightforward way to induce CRISPR/Cas9 gene editing
is to directly delivery Cas9 protein together with sgRNA. This approach
leads to the fastest genome editing as well as the most transient func-
tionality with minimal off-target effects and toxicity, as it requires no
transcription and/or translation. However, pure active Cas9 proteins
are more difficult to obtain and more unstable compared with Cas9
plasmid or mRNA. Moreover, the large size of Cas9 protein brings in-
convenience to its delivery, as many delivery carriers such as viral
vectors are size limited. Therefore polymeric vectors which interact
with its payloads though electrostatic interaction or other inter-
molecular interactions instead of packing the payloads inside are good
alternatives for Cas9 protein delivery.
PEI was one of the several polymers first applied in Cas9 protein
delivery. In a research carried out by Choung et al. [46], PEI was
covalently linked to Cas9 for the use of a minimal amount of polymers.
It also avoided the process of encapsulation and a release step of the
cargo. Then the polymer-modified Cas9 packaged sgRNA, forming
CRISPR complex system and was applied in combating bacterial anti-
biotic resistance, as showed in Fig. 7A. In another research, Xing et al.
modified graphene oxide (GO) with PEI and PEG for Cas9 delivery [47].
In this system, sgRNA would be well protected from enzymatic de-
gradation through electrostatic interactions with modified PEI and π-
stacking interactions with rigid GO plane, thus the stability was
strongly improved. The vector was demonstrated able to induce gene
knock down in mammalian cells, as shown in Fig. 7B.
Apart from PEI based vectors, Gong et al. designed a series of redox-
responsive copolymer for delivery of CRISPR/Cas9 ribonucleoprotein
[48,49]. Those polymers had some segments in common. The disulfide
bonds in the main chain endowed them with redox-responsiveness to
release the payloads rapidly in cytosol where the GSH level is relatively
high. The imidazole side groups that exhibited high positive charge
enabled rapid endosomal escape and PEG segments could shield the
surface charge thus enhance circulation time, as shown in Fig. 7C.
Moreover, the copolymers can be further modified with side chain such
as adamantine and β-cyclodextrin, between which the host-guest in-
teraction strongly enhanced the stability of the complexes and benefited
its application, as shown in Fig. 7D.
3. Applications of cationic polymer based CRISPR/Cas9 system in
gene therapy
As a recently developed gene editing system, CRISPR/Cas9 system is
a promising tool in gene therapy. The system can correct genetic defects
by knocking down the target gene or replacing it with donor DNA, thus
it can be applied in many genetic disorders and nonmonogenic diseases,
such as cancers, cardiovascular diseases, and metabolic disorders. As
mentioned before, the effective intracellular delivery of CRISPR/Cas9
system is the premise of its effective therapeutic action. Polymers, that
endowed with high transfection efficacy, protection of payloads, low
immunogenic and carcinogenic effects, are effective delivery vectors for
CRISPR/Cas9 gene therapy applications.
3.1. Cationic polymer based CRISPR/Cas9 system in cancer gene therapy
Cancer is one of the foremost threats to human health nowadays and
it's acknowledged that cancer is a kind of genome related disease, which
occurs and advances due to a series of mutants in proto-oncogenes and
anti-oncogenes. Therefore, it has been proven an effective method for
cancer treatment by delivering therapeutic agents to correct the genetic
disorders. As a gene editing platform, CRISPR/Cas9 system can silence
oncogene expression, correct mutation, suppress tumor angiogenesis
[5] and as delivery methods, polymeric vectors can achieve protection,
effective intracellular delivery, tumor targeting and controlled release
of CRISPR/Cas9 system.
Several researches convinced that polymeric vector based CRISPR/
Cas9 system targeting proto-oncogenes could disrupt the target gene
and suppress tumor growth. Leong et al. developed a self-assembled
micelle to delivery CRISPR/Cas9 system targeting human papilloma-
virus (HPV) E7 oncogene [38]. HPV E7 can inhibit a kind of cell-cycle
negative regulation protein-retinoblastoma protein (Rb) and lead to un-
controllable cell proliferation [70]. The plasmid which encoded Cas9
and sgRNA targeting HPV E7 was condensed in a polymeric micelle
composed of Pluronic F127 and quaternary ammonium-modified poly
(propylene oxide). The micelles showed effective HPV E7 disruption
Fig. 6. Illustration diagram of optimizing the suitable CLAN for deliverying mCas9/gRNA to macrophages. A series of CLANs were fabricated by tuning the weight of
BHEM-chol to change the surface charge and the fraction of PEG-PLGA to change the PEG density. The celluar uptake of CLANCy5-siRNA was preliminarily tested by
fluorescence-actived cell sorting. CLANs with better uptake were further loaded with Cas9-EGFP/Cas9 mRNA and sgRNA and tested for EGFP expression and EGFP
knockout efficiency. In the end, the optimized CLAN was used to encapsulate mCas9/sgRNA to target NLRP3 gene in macrophages. (Copyright 2019, Springer Nature
Publishing AG) [45].
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and SKOV3 tumor growth suppression, as showed in Fig. 8A. In a re-
search carried out by Wang et al. [41], researchers chose BCR-ABL gene
as target site, cationic lipid-assisted PLGA nanoparticles as delivery
vectors to perform gene knockdown in chronic myeloid leukemia (CML)
cells. It is known that BCR-ABL fusion protein is a kind of consititutive
tyrosine kinase that plays a key role in the development of CML. It
activates a series of proteins and accelerates the proliferation of mye-
loid cells, resulting in CML. Thus the disruption of BCR-ABL gene is an
effective way to treat CML, as showed in Fig. 8B [71]. In another re-
search performed by Leong, oncogene polo-like kinase 1 (Plk1) [72]
was targeted by a kind of cell-penetrating polypeptide based CRISPR/
Cas9 system. The polypeptide was modified with cationic side groups to
condense Cas9 plasmid and sgRNA, forming a kind of polypeptide na-
noparticles. The nanoparticle could be taken up by cells through en-
docytosis as well as pore formation, leading to enhanced cellular up-
take.
Moreover, cationic polymeric vectors can also achieve tumor cell
targeting ability and responsive release of its payloads. Zhang et al.
designed a kind of lipopolymer targeting angiogenic factor -vascular
endothelial growth factor A (VEGFA) to treat Osteosarcoma. Under the
stimulation of VEGFA, endothelial cells are activated to promote agio-
genesis in tumor tissue to delivery nutrient and oxygen [73]. In this
research, the CRISPR/Cas9 plasmid was condensed in PEG-PEI-
Cholesterol (PPC) lipopolymer that had been proven an effective and
safe vector in clinical test, and the lipopolymer was further modified
with OS cell-specific aptamer-LC09 [74] to achieve tumor cell-specific
delivery. In another research carried out by Wei et al., they targeted an
oncogene the mutT homolog1 (MTH1) [75] with a “core-shell” artificial
virus [37]. The artificial virus was conformed of fluorinated LMWPEI
covered by with multifunctional RGD-R8-PEG-HA (RRPH) copolymer,
as showed in Fig. 8C. The RGD-R8 peptide endowed the vector with
targeting ability to tumor and tumor vessel which highly express a kind
of integrin receptor as shown in Fig. 8D [76], and the HA segment
endowed it with charge reverse in tumor tissue that overexpressed
hyaluronidase (HAase) to enhance cellular uptake.
3.2. Cationic polymer based CRISPR/Cas9 system in gene therapy of other
disease
Except for cancer gene therapy, polymer based CRISPR/Cas9 de-
livery system also shows great potential in treating many other diseases.
In a series of researches performed by Wang et al., they utilized ca-
tionic-lipid assisted PLGA nanoparticles (CLANs) for delivery of
CRISPR/Cas9 system in macrophages and B cells to treat type 2 dia-
betes, rheumatoid arthritis or ameliorate inflammatory diseases, as
shown in Fig. 9A. Those CLANs successfully achieved disruption of
Fig. 7. (A) SpCas9 was modified with branched PEI, the spCas9-bPEI condensed sgRNA to form CRISPR nanocomplex. (Copyright 2018, American Chemical Society)
[46] (B) Illustration of the intracellular delivery of GO-PEG-PEI based Cas9/sgRNA delivery system. Cas9/sgRNA complex was loaded in GO-PEG-PEI through
electrostatic and π-stacking interactions. After taken up through endocytosis, the complex escaped from endosome and transported into nucleus where Cas9/sgRNA
exhibited their gene editing efficiency. (Copyright 2018, Royal Society of Chemistry) [47] (C) Schematic of the intracellular delivery of the DNA, mRNA, and Cas9
RNP. After the polyplexes were taken up, the polymers were able to achieve effective endosomal escape owing to positive charged imidazole groups. When they
appeared in the cytosol, the disulfide bonds were cleaved by GSH and the cationic polymers were converted into neutral polymers, thus releasing the payloads.
(Copyright 2018, American Chemical Society) [49] (D) Illustration of polymeric complexes and chemical structures of the redox-responsive polymers, the cationic
segments were for the conjugation of payloads, imidazole groups enabled rapid endosomal escape, disulfide bonds endowed it with redox-responsiveness and
crosslinkers enhanced the stability of the complexes. (Copyright 2018, American Chemical Society) [48].
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Fig. 8. (A) Diagram of HPV oncogene manipulated with the micelle. The micelle was composed of Pluronic F127 and a kind of quaternary ammonium-modified poly
(propylene oxide), condensing Cas9 plasmid and sgRNA. The plasmid CRISPR system could knock down E7 gene, thus inhabited E7 induced Rb degration. (Copyright
2018, Wiley-VCH) [38]; (B) Schematic diagram of CLANs targeting BCR-ABL gene to treat CML. PCas9/gBCR-ABL was encapsulated into cationic-lipid assisted PLGA
nanoparticles. The nanoparticles specifically recognized the BCR-ABL fusion gene in CML cells but not BCR or ABL gene in normal cells, thus exhibit therapeutic
effect on CML and limited side effects. (Copyright 2018, the Royal Society of Chemistry) [41]; (C)The diagram of the composition of artificial virus and its targeting
ability to tumor cells. Plasmid Cas9/sgRNA MTH1 was condensed by fluorinated LMWPEI then covered by RRPH. RGGD-R8 peptide and HA respectively targeted to
integrin αvβ3 receptors and CD44 receptors. (Copyright 2016, American Chemical Society) [37]; (D)Analysis of tumor targeting ability of artificial virus in vivo. The
left figure is a series of in vivo fluorescence imaging of the SKOV3 tumor-bearing nude mice after respectively intravenous injected of RRPH coated and HA coated
PF33/Cas9-hMTH1 nanoparticles. The right figure is ex vivo fluorescence imaging of the tumors and other tissues gained from the tumor-bearing nude mice. Both
figures showed that RRPH coated nanoparticles exhibited high tumor-targeting ability. (Copyright 2016, American Chemical Society) [37].
Fig. 9. (A) The schematic diagram of cationic-lipid assisted PLGA nanoparticles induced macrophages targeted gene disruption. The CRISPR/Cas9 plasmid contained
cell-specific promotor-human CD68 promoter, thus specifically expressed in macrophages and led to gene knockdown. (Copyright 2018, American Chemical Society)
[45]; (B) Schematic depiction shows CRISPR-nanoparticles disrupting bacterial antibiotic resistance gene. SpCas9 was modified with branched PEI to prepare the
spCas9-bPEI and native spCas9 was chosen as comparison, both of them condensed sgRNA targeting mecA in bacterial, resulting in CRISPR nanocomplex and native
complex. The result showed that the PEI modified Cas9 induced more remarkable inhabitation of bacterial growth compared with native complex. (Copyright 2018,
American Chemical Society) [46].
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Ntn1 gene in macrophages with CRISPR/Cas9 plasmid for type 2 dia-
betes treatment. To avoid undesired gene disrupting in other cells, the
Cas9 plasmid was designed with CD68 promoter which was able to
drive specific plasmid expression in macrophages, thus achieve cell-
specific gene editing [43]. In another research, a library of CLANs were
fabricated to optimize delivery of CRISPR/Cas9 plasmids to B cells and
finally CLANs with 40.30% PEG density and 12.2 mV surface charge
were chosen. The CLAN based CRISPR/Cas9 plasmid system knocked
down B-cell activating factor receptor (BAFFR) [77] gene and B220
gene in B cells and showed alleviation of rheumatoid arthritis in mice
[42]. The nanoparticles were also qualified to delivery Cas9 mRNA/
sgRNA. In the research, CLANs were optimized to disrupt NLRP3 gene
in macrophages. The knockout of NLRP3 showed potential in ameli-
orating type2 diabetes, peritonitis as well as septic shock [45]. In ad-
dition to mammalian cells, polymer based CRISPR/Cas9 delivery
system was also used in bacterial. Chung et al. utilized bPEI-derivatized
Cas9 to complex with sgRNA targeting methicillin resistance gene-
mecA. This strategy could achieve effective delivery into bacterial with
minimal amount of vectors, which was hard due to the cell wall. The
delivery system was introduced into methicillin-resistant Staphylococcus
Aureus (MRSA) and resulted in distinct growth inhabitation, as shown
in Fig. 9B [46].
4. Conclusion and perspectives
The development of this novel CRISPR/Cas9 gene editing platform
has revolutionized the field of gene therapy. Researchers have revealed
its application in monogenic disorders (i.e., cataracts, hereditary tyr-
osinemia) as well as in non-monogenetic diseases (i.e., hypercholes-
terolaemia, cancers). To achieve its function, the effective intracellular
delivery of CRISPR/Cas9 components is necessary and great effort has
been made in developing novel delivery strategies. Among them, ca-
tionic polymeric vectors stand out from the crowd for their unique
properties (i.e., low immunogenicity and carcinogenicity, less limitation
in payloads size, or protection of cargos). Besides to those basic prop-
erties, the most exciting part is the further modification of the polymers
(i.e., for targeting ability). Connected with specific peptides, antibodies,
aptamers or other molecules, polymers are able to deliver their cargos
to specific cell types [78]. Targeted delivery can selectively accumulate
the cargos in the disease area, thus reduces the related side effects.
Considering the potential risk of off-targeting effect of CRISPR/Cas9
system, accurate targeted delivery is necessary for its clinical applica-
tion. Current researches have achieved targeted delivery of CRISPR/
Cas9 system to tumor cells with polymeric vectors in form of aptamer-
functionalized lipopolymer [36] or “core-shell” artificial virus [37],
while further researches can expand the application in other cells and
tissues like immune cells, cardiovascular epithelial cells, liver and so
on. Stimulus-sensitive release system is another effective tool in poly-
meric delivery vectors. Through modification, polymers can response to
diverse stimulus like PH, redox, temperature, light, enzyme and so forth
[79]. Those responses endow polymers with ability to retain their
cargos in circulation, concentrate at the desired site and desired time,
enhance cellular internalization and achieve effective drug release [80].
According to current researches in polymeric vectors for CRISPR/Cas9
delivery, the “core-shell” artificial virus can response to the hyalur-
onidase overexpressed in tumor tissue to achieve charge reverse and
enhanced cellular uptake of CRISPR/Cas9 plasmid [37]. And the redox-
responsive copolymers can response to GSH in cytoplasm to effectively
release CRISPR/Cas9 ribonucleoproteins [48,49]. The application of
stimulus-sensitive polymeric delivery system is worth trying in further
CRISPR/Cas9 based gene therapy. In addition, polymeric architectures
like hydrogels and micro or nanospheres are able to provide additional
advantage of sustained release [81,82]. These structures serve as re-
servoirs of therapeutic substances to keep long-term effective plasma
concentration, resulting in sustained therapeutic effect and avoiding the
need of repeated administration. Moreover, stimulus-sensitive release
and targeting ability can also be achieved in those architectures with
further modification of the polymeric units, endowing them with ac-
curate, efficient and long-term therapeutic effect. The application of
those polymeric structures in CRISPR/Cas9 delivery is an attracting
field worthy of further research.
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